文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

加纳15岁及以上人群mRNA新冠疫苗安全性:一项队列事件监测研究

Safety of mRNA COVID-19 vaccines among persons 15- years and above in Ghana: A cohort event monitoring study.
PubMed 文献 · Vaccine · 2024-10-23

在加纳7个固定疫苗接种中心开展前瞻性队列事件监测,纳入4678名接种Pfizer-BioNTech或Moderna mRNA新冠疫苗的15岁及以上人群(含孕妇)。17.4%(95%CI 16.3%–18.5%)出现免疫接种后不良事件(AEFI),Moderna接种者发生率20.4%高于Pfizer-BioNTech接种者14.0%;未报告严重AEFI;Cox回归显示Pfizer-BioNTech较Moderna的AEFI风险低37%。

要点

  • 17.4%(95%CI 16.3%–18.5%)的接种者出现AEFI,未报告严重AEFI。
  • Moderna接种者AEFI发生率20.4%,高于Pfizer-BioNTech接种者的14.0%。
  • Cox回归显示Pfizer-BioNTech较Moderna的AEFI风险低37%。

核心结论

  • 加纳mRNA新冠疫苗耐受性良好,无显著安全性问题,全身和局部事件报告与两疫苗产品特性摘要一致。
  • 研究结果可作为应对疫苗犹豫的重要倡导工具,并为中低收入国家在 future 大流行中开展主动监测提供模型。

研究设计与样本

  • 前瞻性队列事件监测研究,在加纳16个地区中6个地区的7个固定疫苗接种中心开展。
  • 纳入15岁及以上接种mRNA新冠疫苗者(含孕妇),2021年11月开始招募,最后一名参与者随访至2022年8月。
  • 接种后第1、7、28天及第二剂后至91天随访,AEFI按MedDRA 26.1版最低层级术语描述。
  • 共纳入4678名接种Pfizer-BioNTech或Moderna新冠疫苗者,平均年龄32.9岁(SD±14.4)。

主要发现

  • 17.4%(95%CI 16.3%–18.5%)的参与者发生AEFI。
  • Moderna接种者AEFI发生率为20.4%,Pfizer-BioNTech接种者为14.0%。
  • 最常见五种AEFI为注射部位疼痛、头痛、头晕、疲劳和发热。
  • 研究期间未报告严重AEFI。
  • 疫苗接种中心和慢性病史影响AEFI发生风险;Cox比例风险回归显示Pfizer-BioNTech较Moderna的AEFI风险低37%。

临床怎么用

  • 作者认为研究结果可作为应对疫苗犹豫的重要倡导工具,供各国规划新冠疫苗常规接种时使用。
  • 作者认为该主动监测研究可作为药物警戒体系薄弱的中低收入国家在 future 大流行中开展类似研究的模型。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The development of COVID-19 vaccines during the pandemic occurred with an unprecedented speed, requiring extraordinary post-approval safety monitoring to facilitate ongoing evaluation of their benefit-risk profile. In Ghana, the Food and Drugs Authority granted emergency use authorization to six of these vaccines including the two mRNA COVID-19 vaccines, namely, Pfizer-BioNTech and Moderna COVID-19 vaccines. The objective of the study was to estimate the incidence of adverse events following immunization (AEFIs) and adverse events of special interest (AESIs) in persons vaccinated with mRNA COVID-19 vaccines, and to identify factors associated with the development of AEFIs. METHODS: We conducted a prospective cohort event monitoring study in seven selected static vaccination center in six of Ghana's 16 regions. The choice of regions was based on their geographical locations and the incidence rate of COVID-19 at the time of the study. The study was conducted with people aged 15 years and older who were vaccinated with mRNA COVID-19 vaccines, including pregnant women. Study participants were recruited starting in November 2021, with the last participant followed up in August 2022. Persons vaccinated were followed up on days 1, 7, and 28 post-dose 1 and up to 91 days after dose 2. AEFIs were described with the most specific, or lowest-level, term using the Medical Dictionary for Regulatory Activities (MedDRA) version 26.1. Frequencies of AEFIs after each vaccine dose and vaccination center were determined. Cox-proportional hazard regression was used to assess the independent risk factors associated with the incidence of AEFI among the participants. RESULTS: Overall, 4678 persons who received Pfizer-BioNTech or Moderna COVID-19 vaccines from the seven vaccination centers were enrolled in the study. The mean age of participants was 32.9 years (SD ± 14.4). A total of 17.4 % (95 % CI: 16.3 % to 18.5 %) of participants experienced AEFI, with a higher incidence among Moderna COVID-19 vaccine recipients (20.4 %) compared to Pfizer-BioNTech COVID-19 vaccine recipients (14.0 %). The top five common AEFIs included injection site pain, headache, dizziness, fatigue, and fever. No serious AEFIs were reported during the study. Factors such as vaccination center and history of chronic medical conditions influenced the risk of experiencing an AEFI. Cox-proportional hazard regression revealed a 37 % lower risk of AEFI with the Pfizer-BioNTech COVID-19 vaccine compared to the Moderna COVID-19 vaccine. CONCLUSION: The study on mRNA COVID-19 vaccines in Ghana showed that the vaccines are tolerated well with no significant safety concerns. Reports of systemic and local events were consistent with those reported in the summary of product characteristics of the two vaccines. The study's outcome showed that there were no safety issues with mRNA COVID-19 vaccines in Ghana. The results of this study can be used as a crucial advocacy tool to address vaccine hesitancy as countries plan to routinize COVID-19 vaccines. Additionally, the active monitoring study serves as a model for such studies in low- to middle-income countries (LMICs) with weak pharmacovigilance systems during future pandemics.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Darko DM, Seaneke SK, Karikari-Boateng E, et al. Safety of mRNA COVID-19 vaccines among persons 15- years and above in Ghana: A cohort event monitoring study. Vaccine. 2024. PMID: 39447252. doi:10.1016/j.vaccine.2024.126460

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。